Get started
Author

Joanne McCaigue

Observed name: J. McCaigue
ORCID: 0009-0001-0722-7860
Observed ORCID: 0009-0001-0722-7860
OpenAlex ID: A5062142470
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies
2020 · Caitlin L. Costello, Adam D. Cohen, et al. · Blood · 77
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
2022 · Susan F. Slovin, Tanya B. Dorff, et al. · Journal of Clinical Oncology · 52
Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Susan F. Slovin, Xin Gao, et al. · Clinical Cancer Research · 29
Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
2023 · Bhagirathbhai Dholaria, Mehmet H. Kocoglu, et al. · Blood · 26
Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System
2021 · Caitlin Costello, Ben A Derman, et al. · Blood · 24
728 Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers
2022 · Jason Henry, David Oh, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
2025 · Hubert Tseng, Bhagirathbhai Dholaria, et al. · Nature Communications · 10
PDF
A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort
2024 · Bhagirathbhai Dholaria, Leyla O. Shune, et al. · Blood · 10
PDF
46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors
2022 · D. Oh, J. Henry, et al. · Immuno-Oncology Technology · 8
Abstract CT071: Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy
2024 · Bhagirathbhai Dholaria, Leyla Shune, et al. · Cancer Research · 7
OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Bhagirathbhai Dholaria, Mehmet Kocoglu, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
2024 · D. Oh, P. Vu, et al. · Immuno-Oncology Technology · 4
PDF
A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C)
2025 · Dr. Bhagirathbhai Dholaria, Mehmet H. Kocoglu, et al. · Transplantation and Cellular Therapy · 3
Abstract CT070: Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion
2024 · Sabrina Haag, Jeff D. Eskew, et al. · Cancer Research · 2
Supplementary Data from Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Susan F. Slovin, Xin Gao, et al.
Data from Phase I Trial of P-PSMA-101 CAR T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Susan F. Slovin, Xin Gao, et al.
Clinical Activity of P-BCMA-ALLO1, an Allogeneic BCMA Targeting CAR-T, in Patients with Relapsed Refractory Multiple Myeloma (RRMM) and Extramedullary Disease
2025 · Siddhartha MD Ganguly, Caitlin Costello, et al. · Transplantation and Cellular Therapy
Works count: 17
Citation count: 271
H-index: 8
I10-index: 8
Year
Topic
Type